UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 21, 2012
STEVIA CORP.
(Exact Name of Registrant as Specified in its Charter)
Nevada 333-152365 98-0537233
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
7117 US 31 S
Indianapolis, IN 46227
(Address of Principal Executive Office) (Zip Code)
Registrant's telephone number, including area code: (888) 250-2566
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2 below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
SECTION 1 - REGISTRANT'S BUSINESS AND OPERATIONS
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
SUPPLY AGREEMENT
On February 21, 2012, Stevia Corp. (the "Company") entered into a Supply
Agreement (the "Supply Agreement") with Guangzhou Health China Technology
Development Company Limited, a foreign-invested limited liability company
incorporated in the People's Republic of China ("Guangzhou Health"). Under the
terms of the Supply Agreement, the Company will sell dry stevia plant materials,
including stems and leaves ("Product") exclusively to Guangzhou Health. For the
first two years of the agreement, Guangzhou Health will purchase all Product
produced by the Company. Starting with the third year of the agreement, the
Company and Guangzhou Health will review and agree on the quantity of Product to
be supplied in the forthcoming year, and Guangzhou Health will be obliged to
purchase up to 130 percent of that amount. The specifications and price of
Product will also be revised annually according to the mutual agreement of the
parties. The term of the Supply Agreement is five years with an option to renew
for an additional four years.
The foregoing description is qualified in its entirety by reference to the
Supply Agreement, a copy of which appears as Exhibit 10.1 to this Form 8-K and
is incorporated by reference to this Item 1.01.
SECTION 8 - OTHER EVENTS
ITEM 8.01 OTHER EVENTS.
COOPERATIVE AGREEMENT
On February 21, 2012, the Company also entered into a Cooperative Agreement
(the "Cooperative Agreement") with Guangzhou Health. Under the terms of the
Cooperative Agreement, the parties agree to explore potential technology
partnerships with the intent of formalizing a joint venture to pursue the most
promising technologies and businesses. The parties also agree to conduct trials
to test the efficacy of certain technologies as applied specifically to the
Company's business model as well as the marketability of harvests produced
utilizing such technologies. Guangzhou Health will share all available
information of its business structure and technologies with the Company, subject
to the confidentiality provisions of the Cooperative Agreement. Guangzhou Health
will also permit the Company to enter its premises and grow-out sites for
purposes of inspection and will, as reasonably requested by the Company, supply
without cost, random samples of products and harvests for testing.
The foregoing description is qualified in its entirety by reference to the
Cooperative Agreement, a copy of which appears as Exhibit 99.1 to this Form 8-K
and is incorporated by reference to this Item 8.01.
2
SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
Exhibit No. Description
----------- -----------
10.1 Supply Agreement, dated February 21, 2012
99.1 Cooperative Agreement, dated February 21, 2012
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: February 27, 2012 STEVIA CORP.
By: /s/ George Blankenbaker
---------------------------------------
George Blankenbaker
President
4